Webinar: ACR/CHEST ILD Guidelines in Practice| Video: All the Lonely People

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Useful Data Made Easy: The ACR RISE Registry

  |  

A qualified clinical data registry, RISE helps clinicians measure their performance on quality measures, identify ways to improve their patient care experience, navigate Medicare reporting and demonstrate the value of rheumatology to key influencers. Practices must join no later than June 30 to use RISE for 2023 Traditional MIPS or Advancing Rheumatology Patient Care MVP reporting.

Rheumatology Research Foundation Supports High-Risk, High-Reward Ideas

Leslie Mertz, PhD  |  

Now in the second year of his 2021–2023 term as the Rheumatology Research Foundation president, V. Michael Holers, MD, a professor of medicine and immunology and the Smyth Professor of Rheumatology at the University of Colorado, Denver, is looking forward to fortifying and expanding the Foundation’s missions in the framework of its new strategic plan.

FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

  |  

In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Winter 2023’s Awards, Appointments & Announcements in Rheumatology

  |  

Akiko Iwasaki, PhD, Receives the 2022 Lupus Insight Prize   In June 2022, the Lupus Research Alliance (LRA) awarded its Lupus Insight Prize to Akiko Iwasaki, PhD, for her discovery of the link between endogenous retroviruses and systemic lupus erythematosus (SLE). Dr. Iwasaki, who is a Sterling Professor of Immunobiology and a professor of dermatology,…

ACR Convergence 2022 Closing Session Discusses Research Highlights

  |  

PHILADELPHIA—Expert panelists gathered in the closing session at ACR Convergence 2022 to give their take on what they saw as some of the most notable research findings and other insights to come out of the meeting, touching on a number of topics on the leading edge of the field. COVID-19 Prophylaxis & Vaccinations Alfred Kim,…

Top 10 Tricks for the Management of Dry Mouth

  |  

PHILADELPHIA—Whether due to Sjögren’s disease or something else, dry mouth is a common chief complaint from patients with rheumatic illnesses. Dry mouth isn’t life-threatening, but it can have a serious impact on quality of life. Sialogogues like cevimeline and pilocarpine may benefit some, but not all, patients, but cholinergic side effects often limit their usefulness….

How to Welcome and Care for Gender-Diverse Patients

  |  

PHILADELPHIA—Acknowledging the complexities of medical care for transgender (trans) and nonbinary or gender-diverse patients and emphasizing the urgency of doing it right, two experts offered guideposts to clinicians in an ACR Convergence 2022 session titled Dignity and Respect: How to Welcome and Care for Gender Diverse Patients in Your Practice, with advice on providing clinical…

ACR Image Competition 2022 Results, Part 3

Masaki Itagane, MD  |  

Localized Scleroderma in Anti-NXP2-Antibody Positive Dermatomyositis A 67-year-old woman presented with erythematous, indurated skin on her left flanks. She had been diagnosed with dermatomyositis one year earlier when proximal muscle weakness, dysphagia and skin rash developed (see Figure A). Tests at the time showed the presence of anti-NXP2 and anti-Ro52 antibodies, as well as pathological…

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

  |  

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…